Neuron23, Inc.

American clinical stage biotechnology company at South San Francisco in California, founded in 2018, which develops precision medicines for neurological and immunological disease. Works on small molecule inhibitors of leucine rich repeat kinase 2 for Parkinson's disease and of Bruton's tyrosine kinase for multiple sclerosis, pairs its candidates with genetic biomarkers and companion diagnostics developed on a machine learning platform, and runs its own discovery chemistry, biology and translational and clinical development.